Singapore markets closed

C4 Therapeutics, Inc. (CCCC)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
5.0000+0.0200 (+0.40%)
At close: 04:00PM EDT
4.9682 -0.03 (-0.64%)
Pre-market: 09:01AM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 344.03M
Enterprise value 155.56M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)13.60
Price/book (mrq)1.33
Enterprise value/revenue 7.76
Enterprise value/EBITDA 0.12

Trading information

Stock price history

Beta (5Y monthly) 3.23
52-week change 346.20%
S&P500 52-week change 323.49%
52-week high 311.8800
52-week low 31.0600
50-day moving average 36.7466
200-day moving average 34.9327

Share statistics

Avg vol (3-month) 31.71M
Avg vol (10-day) 31.11M
Shares outstanding 568.81M
Implied shares outstanding 669.01M
Float 852.47M
% held by insiders 111.74%
% held by institutions 184.64%
Shares short (15 May 2024) 411.34M
Short ratio (15 May 2024) 48.63
Short % of float (15 May 2024) 420.08%
Short % of shares outstanding (15 May 2024) 416.49%
Shares short (prior month 15 Apr 2024) 49.56M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)-979.99%

Management effectiveness

Return on assets (ttm)-20.86%
Return on equity (ttm)-48.42%

Income statement

Revenue (ttm)20.04M
Revenue per share (ttm)0.37
Quarterly revenue growth (yoy)-19.20%
Gross profit (ttm)N/A
EBITDA -130.8M
Net income avi to common (ttm)-126.07M
Diluted EPS (ttm)-2.3700
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)258.19M
Total cash per share (mrq)3.75
Total debt (mrq)69.72M
Total debt/equity (mrq)26.99%
Current ratio (mrq)5.08
Book value per share (mrq)3.76

Cash flow statement

Operating cash flow (ttm)-91.83M
Levered free cash flow (ttm)-51.13M